Overview

Observational Study to Evaluate LDL-C Lowering Effect of Ezetimibe (0653-070)

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
To evaluate the LDL-C lowering in south african patients with primary hypercholesterolaemia after the addition of ezetimibe 10mg /day to ongoing therapy with a statin.
Phase:
Phase 3
Details
Lead Sponsor:
Merck Sharp & Dohme Corp.
Treatments:
Ezetimibe